Clinical Trial Update: Zylet vs TobraDex in Blepharokeratoconjunctivitis [Phase 4]

View source ↗

Summary

Phase 4 trial comparing Zylet and TobraDex for Blepharokeratoconjunctivitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blepharokeratoconjunctivitis

Drugs mentioned

• Tobradex (tobramycin and dexamethasone)
• Zylet (loteprednol etabonate and tobramycin)

Snippet

Sponsor: Bausch & Lomb Incorporated | Conditions: Blepharokeratoconjunctivitis | Phase 4 | Status: COMPLETED